Dr. Ostacher is Professor of Psychiatry and Behavioral Sciences at Stanford University School of Medicine. He is the Director of the Bipolar and Depression Research Program at the Veterans Affairs Palo Alto Health Care System in California, the Director of Advanced Fellowship Training in Mental Illness Research and Treatment for MDs and the Site Director at the VA Palo Alto for Advanced Fellowship Training for Stanford. A graduate of Vanderbilt University School of Medicine, the Harvard School of Public Health, and Harvard Medical School, he completed his training at The Cambridge Health Alliance at Harvard Medical School in Adult Psychiatry, Public Psychiatry, and Geriatric Psychiatry. He is the Digital Content Editor for the journal Evidence-Based Mental Health and is on the editorial boards of Bipolar Disorders, the International Journal of Bipolar Disorders, the Journal of Clinical Psychiatry, Current Psychiatry, and Psychiatric Annals. He is the Co-Chair of the Bipolar Disorder Task Group of the National Network of Depression Centers in the United States, is a member of the United States Department of Veterans Affairs/Department of Defense Bipolar Disorder Clinical Practice Guideline Workgroup, and is the editor for the Bipolar and Related Disorders chapter of the DSM-5 Text Revision (to be published in March 2022 by American Psychiatric Association Publishing). His primary research interest is in large clinical trials mental health and addiction, and the implementation of evidence-based mental health practices.
Michael Ostacher critically appraises and summarises a recent Cochrane systematic review, which presents the latest best evidence on the efficacy of lamotrigine in the maintenance treatment of bipolar disorder.[read the full story...]
Michael Ostacher provides a robust appraisal of a recent UK cohort study that suggests bipolar disorder patients taking lithium had reduced self-harm and unintentional injury rates, when compared with patients taking valproate, olanzapine or quetiapine.[read the full story...]
Michael Ostacher considers the findings of the CEQUEL trial, which asks: Does lamotrigine treat bipolar depression when added to quetiapine, and does adding folic acid help any more?[read the full story...]
Michael Ostacher provides some context and ideas for the JoinMQ conference on research priorities for bipolar disorder, which is taking place in London on 9-10 November 2015.[read the full story...]